Yahoo Finance4d
Viralgen and Axovia partner to manufacture an investigational gene therapy for retinal dystrophy in Bardet-Biedl Syndrome (BBS) patients
Bardet-Biedl Syndrome (BBS) is a genetic condition that causes multi-system disorders, with obesity and progressive retinal dystrophy being among the most debilitating symptoms. This disease ...
Morningstar19d
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer
Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Penny Fleck as chief ...
Hosted on MSN3d
Viralgen and Axovia to develop gene therapy for retinal dystrophy
Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...
Pharm Exec4d
Viralgen and Axovia Partner to Manufacture Gene Therapy for Retinal Dystrophy in Bardet-Biedl Syndrome Patients
Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic ...